Stock flies high on Clearside’s PhIII macular edema trial results as drug improves vision
The stock is soaring at Clearside Biomedical $CLSD, a Georgia-based biopharma developing eye drugs that tackle blindness, following news that one of its treatment improved vision in patients.
The results are from a Phase III trial testing the treatment against macular edema associated with inflammation of a part of the eye known as uveitis. Macular edema is the buildup of fluid in the part of the eye known as macula, resulting in distorted vision.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.